Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 13 | 2020 | 66 | 3.560 |
Why?
|
| Chickens | 10 | 2020 | 32 | 1.400 |
Why?
|
| Autoantibodies | 5 | 2016 | 71 | 1.230 |
Why?
|
| Ovary | 7 | 2013 | 21 | 1.120 |
Why?
|
| Biomarkers, Tumor | 3 | 2016 | 179 | 0.960 |
Why?
|
| Disease Models, Animal | 9 | 2013 | 570 | 0.910 |
Why?
|
| Antibodies, Neoplasm | 3 | 2009 | 13 | 0.870 |
Why?
|
| Selenium-Binding Proteins | 2 | 2016 | 2 | 0.860 |
Why?
|
| Primary Ovarian Insufficiency | 2 | 2016 | 7 | 0.720 |
Why?
|
| Infertility, Female | 2 | 2016 | 12 | 0.720 |
Why?
|
| Inflammasomes | 1 | 2020 | 17 | 0.680 |
Why?
|
| Antigens, Neoplasm | 3 | 2009 | 38 | 0.620 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 3 | 0.560 |
Why?
|
| Endometriosis | 1 | 2016 | 7 | 0.560 |
Why?
|
| Follicle Stimulating Hormone | 5 | 2008 | 17 | 0.500 |
Why?
|
| Menopause | 5 | 2008 | 94 | 0.500 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2013 | 4 | 0.450 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2013 | 5 | 0.440 |
Why?
|
| Ovarian Follicle | 4 | 2009 | 7 | 0.440 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 47 | 0.440 |
Why?
|
| Animals | 11 | 2020 | 3391 | 0.430 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 108 | 0.410 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2013 | 103 | 0.410 |
Why?
|
| Female | 23 | 2020 | 14516 | 0.400 |
Why?
|
| Humans | 21 | 2020 | 26260 | 0.280 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 123 | 0.280 |
Why?
|
| Neoplasm Proteins | 1 | 2005 | 51 | 0.250 |
Why?
|
| RNA, Messenger | 3 | 2020 | 264 | 0.250 |
Why?
|
| Neoplasm Staging | 5 | 2013 | 314 | 0.240 |
Why?
|
| Adult | 12 | 2016 | 7447 | 0.230 |
Why?
|
| Corpus Luteum | 2 | 2004 | 5 | 0.220 |
Why?
|
| C-Reactive Protein | 2 | 2014 | 99 | 0.220 |
Why?
|
| Muscle, Skeletal | 1 | 2006 | 357 | 0.210 |
Why?
|
| Pain | 1 | 2006 | 389 | 0.210 |
Why?
|
| Estradiol | 1 | 2002 | 37 | 0.210 |
Why?
|
| Inflammation | 3 | 2020 | 265 | 0.200 |
Why?
|
| Receptors, Gonadotropin | 1 | 2001 | 1 | 0.190 |
Why?
|
| Granulosa Cells | 1 | 2001 | 2 | 0.190 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2014 | 176 | 0.190 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 337 | 0.170 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2020 | 15 | 0.170 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 58 | 0.170 |
Why?
|
| Menopause, Premature | 1 | 1999 | 6 | 0.160 |
Why?
|
| Middle Aged | 9 | 2016 | 8600 | 0.160 |
Why?
|
| Cytokines | 1 | 2020 | 226 | 0.150 |
Why?
|
| Immunoassay | 2 | 2009 | 37 | 0.150 |
Why?
|
| ROC Curve | 1 | 2016 | 137 | 0.130 |
Why?
|
| Menstrual Cycle | 2 | 2007 | 16 | 0.130 |
Why?
|
| Case-Control Studies | 1 | 2016 | 566 | 0.120 |
Why?
|
| Warfare | 1 | 2014 | 10 | 0.120 |
Why?
|
| Terrorism | 1 | 2014 | 12 | 0.120 |
Why?
|
| Cytomegalovirus | 1 | 2014 | 15 | 0.120 |
Why?
|
| Antibodies, Viral | 1 | 2014 | 53 | 0.110 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 16 | 0.110 |
Why?
|
| Adolescent | 2 | 2016 | 2079 | 0.110 |
Why?
|
| Young Adult | 2 | 2016 | 1886 | 0.110 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 4675 | 0.110 |
Why?
|
| Violence | 1 | 2013 | 31 | 0.110 |
Why?
|
| Estrone | 3 | 2008 | 8 | 0.100 |
Why?
|
| Pregnanediol | 3 | 2008 | 7 | 0.100 |
Why?
|
| Luteinizing Hormone | 3 | 2008 | 9 | 0.100 |
Why?
|
| Follicular Fluid | 2 | 2002 | 3 | 0.100 |
Why?
|
| Stress, Psychological | 1 | 2014 | 212 | 0.100 |
Why?
|
| Fluorocarbons | 1 | 2011 | 10 | 0.090 |
Why?
|
| Albumins | 1 | 2011 | 18 | 0.090 |
Why?
|
| Image Enhancement | 1 | 2011 | 46 | 0.090 |
Why?
|
| Flax | 1 | 2010 | 1 | 0.090 |
Why?
|
| Ultrasonography, Doppler | 1 | 2010 | 14 | 0.090 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2010 | 17 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 1 | 2010 | 33 | 0.090 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2009 | 10 | 0.080 |
Why?
|
| Aged | 2 | 2016 | 8764 | 0.080 |
Why?
|
| Chromatography, Liquid | 1 | 2009 | 22 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2009 | 21 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2009 | 21 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2011 | 222 | 0.080 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2009 | 20 | 0.080 |
Why?
|
| Cyclooxygenase 1 | 1 | 2008 | 6 | 0.080 |
Why?
|
| Algorithms | 1 | 2011 | 363 | 0.080 |
Why?
|
| Cyclooxygenase 2 | 1 | 2008 | 27 | 0.080 |
Why?
|
| Luteal Phase | 1 | 2008 | 2 | 0.080 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2007 | 2 | 0.070 |
Why?
|
| Pulsatile Flow | 1 | 2007 | 4 | 0.070 |
Why?
|
| Vascular Resistance | 1 | 2007 | 10 | 0.070 |
Why?
|
| Blood Flow Velocity | 1 | 2007 | 16 | 0.070 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2007 | 7 | 0.070 |
Why?
|
| Ovarian Cysts | 1 | 2007 | 3 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2007 | 65 | 0.070 |
Why?
|
| Blotting, Western | 1 | 2007 | 133 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2007 | 210 | 0.070 |
Why?
|
| Disease Progression | 1 | 2009 | 687 | 0.070 |
Why?
|
| Cross-Cultural Comparison | 1 | 2006 | 36 | 0.070 |
Why?
|
| Factor Analysis, Statistical | 1 | 2006 | 61 | 0.070 |
Why?
|
| Logistic Models | 1 | 2006 | 365 | 0.060 |
Why?
|
| Random Allocation | 2 | 2010 | 119 | 0.060 |
Why?
|
| Residence Characteristics | 1 | 2006 | 209 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2006 | 1738 | 0.060 |
Why?
|
| Pain Measurement | 1 | 2006 | 454 | 0.060 |
Why?
|
| Cross-Sectional Studies | 1 | 2006 | 853 | 0.050 |
Why?
|
| United States | 2 | 2006 | 1989 | 0.050 |
Why?
|
| Inhibins | 1 | 2002 | 2 | 0.050 |
Why?
|
| Ovulation Induction | 1 | 2002 | 2 | 0.050 |
Why?
|
| Fertilization in Vitro | 1 | 2002 | 3 | 0.050 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2002 | 5 | 0.050 |
Why?
|
| Androstenedione | 1 | 2002 | 5 | 0.050 |
Why?
|
| Lymphokines | 1 | 2002 | 8 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 13 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 9 | 0.050 |
Why?
|
| Progesterone | 1 | 2002 | 11 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2002 | 42 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2002 | 66 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 53 | 0.050 |
Why?
|
| Receptors, LH | 1 | 2001 | 1 | 0.050 |
Why?
|
| CHO Cells | 1 | 2001 | 10 | 0.050 |
Why?
|
| Cricetinae | 1 | 2001 | 35 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2001 | 109 | 0.050 |
Why?
|
| Depression | 2 | 2014 | 407 | 0.040 |
Why?
|
| Risk Factors | 1 | 2006 | 2265 | 0.040 |
Why?
|
| Cardiolipins | 1 | 1999 | 1 | 0.040 |
Why?
|
| Antigens, Nuclear | 1 | 1999 | 2 | 0.040 |
Why?
|
| Blood Donors | 1 | 1999 | 4 | 0.040 |
Why?
|
| Thyroid Gland | 1 | 1999 | 9 | 0.040 |
Why?
|
| Causality | 1 | 1999 | 52 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2014 | 427 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 485 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 1999 | 80 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 677 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2006 | 3366 | 0.040 |
Why?
|
| Aging | 2 | 2003 | 1538 | 0.030 |
Why?
|
| Cognition | 1 | 2003 | 1291 | 0.030 |
Why?
|
| Israel | 1 | 2014 | 14 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2014 | 34 | 0.030 |
Why?
|
| Crime Victims | 1 | 2013 | 25 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 7 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 60 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2004 | 1343 | 0.020 |
Why?
|
| Ovulation | 1 | 2008 | 1 | 0.020 |
Why?
|
| Oviposition | 1 | 2008 | 3 | 0.020 |
Why?
|
| Diet | 1 | 2010 | 170 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2004 | 1838 | 0.020 |
Why?
|
| European Continental Ancestry Group | 1 | 2008 | 1 | 0.020 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2008 | 1 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 1074 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 95 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2008 | 151 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2007 | 26 | 0.020 |
Why?
|
| Body Constitution | 1 | 2004 | 3 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 81 | 0.010 |
Why?
|
| Postmenopause | 1 | 2003 | 49 | 0.010 |
Why?
|
| Income | 1 | 2003 | 72 | 0.010 |
Why?
|
| Women's Health | 1 | 2004 | 178 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2003 | 290 | 0.010 |
Why?
|
| Educational Status | 1 | 2003 | 288 | 0.010 |
Why?
|
| Memory | 1 | 2003 | 299 | 0.010 |
Why?
|
| Chicago | 1 | 2003 | 843 | 0.010 |
Why?
|
| Male | 1 | 2014 | 14124 | 0.010 |
Why?
|